Literature DB >> 10924602

Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma radiation, and photochemical treatment.

E Fiebig1, D F Hirschkorn, V C Maino, J A Grass, L Lin, M P Busch.   

Abstract

BACKGROUND: Functional donor T-lymphocytes in blood components may cause a variety of transfusion complications. A flow cytometric assay based on the measurement of induced CD69 expression may be an alternative to cell proliferation methods in determining the functional status of these cells in blood components. STUDY DESIGN AND METHODS: Seven units of whole blood, RBCs, and platelet concentrates (PCs) were stored under blood bank conditions. Half of 3 PCs each were gamma-radiated or treated with UVA+psoralen; the other half served as controls. Samples were analyzed for phorbolester-induced expression of CD69 as an indicator of cell responsiveness and for exclusion of propidium iodide as a measure of cell membrane integrity and viability.
RESULTS: CD69 inducibility and propidium iodide exclusion decreased exponentially (half-life, 3. 3 and 8.1 days, respectively) during cold blood storage. Irradiation and UVA+psoralen treatment of PCs immediately reduced CD69 inducibility to 21 percent (controls, 82%; p = 0.004) and 12 percent (controls, 95%; p = 0.0008), respectively. The proportion of cells capable of propidium iodide exclusion was similar in treated samples and controls, but it declined faster in the treated samples during subsequent storage.
CONCLUSION: Flow cytometric measurement of CD69 induction can be adapted to provide quantitative assessment of T-cell function in blood components. Results obtained by the CD69 assay are in general agreement with those previously reported by use of proliferation methods; the assay may be useful for special applications in transfusion medicine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924602     DOI: 10.1046/j.1537-2995.2000.40070761.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

2.  Cost implications of implementation of pathogen-inactivated platelets.

Authors:  Jeffrey McCullough; Dennis Goldfinger; Jed Gorlin; William J Riley; Harpreet Sandhu; Christopher Stowell; Dawn Ward; Mary Clay; Shelley Pulkrabek; Vera Chrebtow; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-05-18       Impact factor: 3.157

3.  Transfusion of pathogen-reduced platelet components without leukoreduction.

Authors:  Joycelyn Sim; Wai Chiu Tsoi; Cheuk Kwong Lee; Rock Leung; Clarence C K Lam; Claudia Koontz; Amy Yingjie Liu; Norman Huang; Richard J Benjamin; Hans J Vermeij; Adonis Stassinopoulos; Laurence Corash; Albert K W Lie
Journal:  Transfusion       Date:  2019-03-28       Impact factor: 3.157

4.  Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.

Authors:  Steve Kleinman; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-08-25       Impact factor: 3.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.